Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022604 | 0.82 | MEN1 (0.51) | SIGMAR1MEN1KMT2AATMMAOB | |
| SCHEMBL5867104 | 0.81 | LMNA (0.56) | SIGMAR1MEN1KMT2AATMMAOB | |
| SCHEMBL2230470 | 0.79 | HPGD (0.50) | KMT2ALMNA | |
| SCHEMBL15543392 | 0.79 | HPGD (0.50) | KMT2ALMNA | |
| SCHEMBL57428 | 0.79 | HPGD (0.50) | KMT2ALMNA | |
| SCHEMBL7784231 | 0.79 | HPGD (0.50) | KMT2ALMNA | |
| SCHEMBL7784180 | 0.79 | HPGD (0.50) | KMT2ALMNA | |
| SCHEMBL7787201 | 0.79 | HPGD (0.50) | KMT2ALMNA | |
| SCHEMBL7783839 | 0.79 | HPGD (0.50) | KMT2ALMNA | |
| SCHEMBL3140142 | 0.79 | HPGD (0.50) | KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638639-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7615566-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7524880-B2 | Crystalline form of a substituted pyrrolidine compound | THERAVANCE, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080161577-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-07-03 | — | — | US | disclosed |
| US-20080146649-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-19 | — | — | US | disclosed |
| US-7351718-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351717-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070135482-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070078163-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-04-05 | — | — | US | disclosed |
| US-7183292-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20050277688-A1 | Crystalline form of a substituted pyrrolidine compound | THERAVANCE, INC. | 2005-12-15 | — | — | US | disclosed |
| US-20040254219-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135482-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | SIGMAR1 264/4885MEN1 1247/4885KMT2A 2879/4885 |
| US-20050277688-A1 | Crystalline form of a substituted pyrrolidine compound | PKD2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD1 | SIGMAR1 1865/4885MEN1 3023/4885KMT2A 2699/4885 |
| US-20080161577-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | SIGMAR1 264/4885MEN1 1247/4885KMT2A 2879/4885 |
| US-20040254219-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, ADRA1D | SIGMAR1 151/4885MEN1 1069/4885KMT2A 3243/4885 |
| US-20080146649-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | SIGMAR1 264/4885MEN1 1247/4885KMT2A 2879/4885 |
| US-20070078163-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | SIGMAR1 264/4885MEN1 1247/4885KMT2A 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.